Uncategorized

Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise.

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.

Our CEO accidentally started a book club. Now we’re all dreaming of mega pharma mergers.

Staar’s job cuts come “amid ongoing macroeconomic and geopolitical challenges that have pressured the business,” a spokesperson said. Demand in China, the company’s largest market, has slowed.

The pathologists group wants the HHS to terminate the regulation in light of an executive order from President Trump that calls for federal agencies to “alleviate unnecessary regulatory burdens.”

As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as Eli Lilly offers expanded Zepbound options; and struggling gene therapy biotech bluebird bio goes private in an attempt to stay solvent.

SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for every rare disease, experts say.

SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for neurofibromatosis alive. This method could work for “every rare disease under the sun,” advocates say.

Cost projections for the embattled medical record modernization project range from the VA’s earlier estimate of around $16 billion to an independent evaluation of nearly $50 billion, according to the Government Accountability Office.

Emalex is gearing up for a New Drug Application for ecopipam in Tourette syndrome later this year.